Logo

Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Share this

Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Shots:

  • Gilead entered into a strategic collaboration with Glympse Bio to utilize Glympse’s technology- Glympse Inside in its NASH program to diagnose the stage of NASH as well as early detection of treatment response
  • The focus of the collaboration is to meet highly unmet medical needs and to improve the lives of patients by transforming the disease detection and measuring treatment response
  • Glympse Inside is a pan-disease product engine focusing on transforming disease monitoring and treatment response by integrating synthetic biomarkers with machine learning and AI

Click here to­ read full press release/ article 

Ref: Gilead | Image: Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions